Jonathan Li

@DrJLi

Assistant Professor at the Brigham and Women's Hospital and Harvard Medical School. Physician-scientist with a focus on HIV care, drug resistance and cure.

Vrijeme pridruživanja: rujan 2012.

Tweetovi

Blokirali ste korisnika/cu @DrJLi

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @DrJLi

  1. proslijedio/la je Tweet
    3. velj

    Disappointing, to say the least, but there were concerns that the marginal efficacy observed in the RV144 trial that this was based on was not going to be reproducible. Important result nonetheless, kudos to all who worked on it and participated.

    Poništi
  2. proslijedio/la je Tweet
    3. velj
    Poništi
  3. 25. sij

    Lancet report of 41 cases of the novel () refers to ongoing randomized trial of lopinavir/r+IFN vs placebo, registered Jan 23: . It's open-label, N=80/arm, not on O2, but sat <=94%, outcome is clinical improvement at 28d

    Poništi
  4. proslijedio/la je Tweet
    16. pro 2019.

    and colleagues -ASSIST to the test and found that recommendations for were consistent with those of expert

    Poništi
  5. proslijedio/la je Tweet
    5. pro 2019.

    The November issue of O-F-I-D was a winner, with the electronic table of contents summarized in this link. The cover is also terrific, featuring the early 20th century poster genius Leonetto Cappiello!

    Poništi
  6. proslijedio/la je Tweet

    It's . There were approximately 37.9 million people living with at the end of 2018. 🔹79% had been diagnosed 🔹62% were receiving treatment 🔹53% had achieved suppression of the HIV virus to the point at which they were at low risk of infecting others.

    , , i još njih 3
    Prikaži ovu nit
    Poništi
  7. 23. stu 2019.

    What a great discussion by and will definitely be looking for the Sax sign the next time I’m on service! Lucky to count him as a friend and mentor at the

    Poništi
  8. proslijedio/la je Tweet

    , couldn't get enough of 's clinical reasoning? We've got you covered! Special guest returns for a new clinical unknown presented by !

    Poništi
  9. 22. stu 2019.

    As an HIV researcher, cases like this keep me up at night. It's an uphill fight against human nature as non-HIV researchers can attest to: . Agree that we should be offering once logistics are worked out: funding, consent, monitoring of partner(s).

    Poništi
  10. proslijedio/la je Tweet
    16. stu 2019.

    Proclaiming that you have a cure for HIV (or even advertising that you're only hopeful that you do) is more likely to generate clicks than publishing the gritty reality of cure research. hype-atitis harms people living with HIV!

    , , i još njih 7
    Poništi
  11. 12. stu 2019.

    Great blog post by , including the hype about a company called AGT. They want to 1) enrich for HIV-specific T cells, 2) protect them from HIV somehow, 3) re-infuse into the pts. But details vague, there's no publications and no human studies yet. A case of hype>>facts

    Poništi
  12. proslijedio/la je Tweet

    Yesterday, Nov. 7, marked the 28th anniversary of my HIV announcement. I feel so blessed to be here and want to thank everyone for their support, prayers, and well wishes over these years!

    Poništi
  13. 7. stu 2019.

    Videos now available from a fantastic symposium on organized with , featuring talks by Bob Siliciano, , Boris Juelg, Gaurav Gaiha, Susana Valente, Jim Riley, and Xu Yu.

    Poništi
  14. 5. stu 2019.

    Provocative analysis by of the Promise study showing a far higher frequency of women with delayed viral rebound after stopping ART compared to a mostly male study. But most Promise participants were African: could it also be race and HIV clade-driven?

    Poništi
  15. proslijedio/la je Tweet
    16. lis 2019.

    Hey! Next week is this nice symposium that I helped organize (with and friends), so register if you can attend! I'll be talking about therapeutic vaccines, and we've got bNAbs on the agenda too!

    Poništi
  16. 15. lis 2019.

    A well-written review discussing the pros/cons of ART for HIV spontaneous controllers. ACTG A5308 and other studies show benefit for viremic controllers, but still controversial for those with largely undetectable viral loads and high CD4s.

    Poništi
  17. 14. lis 2019.

    So proud of my team and their work with and the ! There is not a more dedicated group of people working on HIV resistance, reservoirs and an

    Poništi

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·